Vasopressin

Vasopressin; 纯度: 99.68%

Vasopressin 是一种环状九肽,在下丘脑中枢合成。Vasopressin 参与下丘脑-垂体-肾上腺轴,并通过增强促肾上腺皮质激素释放因子的刺激作用调节垂体促肾上腺皮质激素分泌。Vasopressin 也可以作为一种神经递质,通过与特定的 G 蛋白偶联受体结合来发挥其作用。

Vasopressin 

Vasopressin Chemical Structure

CAS No. : 11000-17-2

规格 价格 是否有货 数量
5 mg ¥500 In-stock
10 mg ¥800 In-stock
25 mg ¥1200 In-stock
50 mg ¥2000 In-stock
100 mg ; 询价 ;
200 mg ; 询价 ;

* Please select Quantity before adding items.

Vasopressin 相关产品

相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • Bioactive Compound Library Plus
  • Metabolism/Protease Compound Library
  • FDA-Approved Drug Library
  • Human Endogenous Metabolite Compound Library
  • Drug Repurposing Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Food-Sourced Compound Library
  • Rare Diseases Drug Library
  • Children’s Drug Library
  • Peptide Library

生物活性

Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis, and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of corticotropin releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors[1][2][3].

IC50 & Target

Human Endogenous Metabolite

;

体外研究
(In Vitro)

AVP (0.01 nM-1 μM) induces Ca2+ increase in Chinese hamster ovary cells expressing rat or human V1b receptors[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Vasopressin (0.03-0.3 μg/kg; i.p.) potentiates corticotropin release provoked by exogenous corticoliberin and increases corticotropin secretion subsequent to body water loss[2].
Vasopressin (0.001-0.1 mg/kg; i.p.) potently increases adjacent lying, where rats meeting for the first time lie passively next to each other[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

1084.24

Formula

C46H65N15O12S2

CAS 号

11000-17-2

Sequence Shortening

CYFQNCPR-NH2 (Disulfide Bridge: Cys1-Cys6)

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro:;

DMSO : 100 mg/mL (92.23 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 0.9223 mL 4.6115 mL 9.2231 mL
5 mM 0.1845 mL 0.9223 mL 1.8446 mL
10 mM 0.0922 mL 0.4612 mL 0.9223 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.5 mg/mL (2.31 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.31 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂:;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (2.31 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.31 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.31 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.31 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Baribeau DA, et, al. Oxytocin and vasopressin: linking pituitary neuropeptides and their receptors to social neurocircuits. Front Neurosci. 2015 Sep 24;9:335.

    [2]. Ramos L, et, al. Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor. Neuropsychopharmacology. 2013 Oct;38(11):2249-59.

    [3]. Gal CSL, et, al. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther. 2002 Mar;300(3):1122-30.